Driessen-Kerr.mRNA PRODUCT SYSTEMS
DRIESSEN-KERR
◆
EPI
TIDE™
PEPTIDE MATRIX · DK-7.4
NUTRITIONAL FORMULATION · DK-7.4
LEUILEVALGLNHMBPSPCCRED3K2
9 DECLARED COMPONENTS · DK-7.4
EPITIDE™·DK-7.4·FORMULATION CONCEPT
DK-7.4 · VISUAL PROTOTYPE
VISUAL MOCK-UP · LOT TRACEABILITY TO DEFINE
DRIESSEN-KERR · EPINUTRITION · DK-7.4

EPITIDE™

DK-7.4·FORMULATION
by Driessen-Kerr

Biological Systems · Signal Architecture · DK-7.4

Maintaining lean mass, energy, and recovery fails when delivery is variable, signaling is discontinuous, and evidence is fragmented. DK-7.4 is presented as an architecture to make this problem measurable, modular, and testable — not as a clinical promise.

ABSVariable delivery
SIGDiscontinuous signal
CTXMetabolic context
EVDFragmented evidence
Technical conversation · DK-7.4
Explore the formulation
Discuss the evaluation context, availability, technical materials and possible next steps with the team.

Technical materials are discussed by request. Ingredient and experimental-model literature provides scientific context, not clinical evidence for the complete formulation. Product classification remains to be confirmed; the final label requires product-specific regulatory review.

— 01Failure Modes · Systems View

What breaks
before the outcome.

In applied biology, the bottleneck is rarely a lack of ingredients. It is the distance between what enters the system, the signal that remains available, and what can be measured with confidence.

ABS–0101 / 04

Variable delivery

The same intake can produce different exposures because of matrix, timing, digestion, and metabolic context.

How can the delivered fraction be characterized?
SIG–0202 / 04

Discontinuous signal

A molecular pathway can receive an isolated pulse without an architecture for observing duration, threshold, and noise.

Which signal is actually observable?
CTX–0303 / 04

Changing context

Energy deficit, age, exertion, and recovery alter the system before any intervention can be compared.

What changes across populations?
EVD–0404 / 04

Fragmented evidence

Ingredient literature, formulation characterization, and clinical outcomes answer different questions.

Which evidence is needed to move forward?
DK–7.4 · Thesis

The value lies in turning a biological chain that is difficult to compare into a system of variables that can be characterized, audited, and only then tested.

— 02System Architecture · DK-7.4

The question before the stack

Before discussing ingredients, the problem must be defined: how can variability between intake, signaling, and measurable response be reduced across metabolic contexts? The stack below is a testing architecture, not a clinical outcome.

BCAA / Essential Amino Acids
Phospholipids / Bioactive Metabolites
Cofactors & Energy Support
Composition control · REG / technical verification

The nine components/groups below describe the declared ingredient profile, not a confirmed final formula or an established “six active compounds” category. The final composition is subject to specification and labeling review.

Code
Component · Function / classification
LEU
Free L-LeucineEssential BCAA Amino Acid

Dietary essential amino acid; participates in protein synthesis and energy metabolism.

ILE
L-IsoleucineEssential BCAA Amino Acid

Essential amino acid incorporated into proteins and energy metabolism.

VAL
L-ValineEssential BCAA Amino Acid

Essential amino acid incorporated into proteins; also participates in BCAA metabolism.

GLN
L-GlutamineConditionally Essential Amino Acid

Abundant amino acid involved in nitrogen metabolism and used as a substrate by multiple tissues.

HMB
β-Hydroxy β-Methylbutyrate (HMB)Bioactive Metabolite

Nutritional metabolite derived from leucine; its inclusion is part of the declared composition.

PS
PhosphatidylserineBioactive Phospholipid

Phospholipid found in cell membranes; its role in the composition is not a demonstrated physiological effect.

PC
PhosphatidylcholineStructural Phospholipid

Phospholipid component of the proposed matrix; its technological function depends on the composition and process actually used.

CRE
Creatine MonohydrateEnergy Metabolite

Participates in the creatine–phosphocreatine system, associated with buffering and rapid ATP resynthesis.

D3K2
Vitamin D3 + K2 (MK-7)Fat-Soluble Cofactors

D3 participates in calcium and phosphorus homeostasis; vitamin K is a cofactor for vitamin-K-dependent proteins. These functions are not product claims.

COUNT
9 declared components/groups · final specification under review
Ingredient monographs · LIT / ingredient level

What the literature can—and cannot—say

The ingredient profiles below summarize literature and experimental models, not clinical results for this complete formulation.

LEU · ingredient profile

Free L-Leucine

LIT · ingredient / model
Nutritional / formulation function
Dietary essential amino acid; participates in protein synthesis and energy metabolism.
Mechanism investigated
Nutrient signaling associated with mTORC1 through amino-acid sensors, including Sestrin/GATOR/Rag axes; response depends on context and availability of other amino acids.
Evidence type / population
Human-literature review across aging, exercise, and disuse; ingredient level, not product evidence. Multiple populations and protocols covered by the review; no DK-7.4 population has been studied.
Study duration
Varies across studies; no single duration transfers to the formulation.
Limits / relevance to DK-7.4
Response depends on dose, meal, total protein, age, exercise, and study design. Product exposure and threshold are not inferred.
DOI · LIT
10.1016/j.clnu.2023.08.010
ILE · ingredient profile

L-Isoleucine

LIT · ingredient / model
Nutritional / formulation function
Essential amino acid incorporated into proteins and energy metabolism.
Mechanism investigated
Studied in BCAA metabolism and post-exercise protein synthesis; its specific contribution depends on dietary matrix and protocol.
Evidence type / population
Systematic review of dietary leucine and post-exercise protein synthesis; does not isolate a DK-7.4 benefit. Exercise-study participants and protocols; details vary across the review.
Study duration
Acute and/or differing protocols by study; no product duration established.
Limits / relevance to DK-7.4
Do not treat BCAA ratios or cellular findings as human efficacy of the combination.
DOI · LIT
10.14814/phy2.15775
VAL · ingredient profile

L-Valine

LIT · ingredient / model
Nutritional / formulation function
Essential amino acid incorporated into proteins; also participates in BCAA metabolism.
Mechanism investigated
Studied in BCAA metabolism and post-exercise protein synthesis; an isolated mechanism is not a formula effect.
Evidence type / population
Systematic review of post-exercise literature including BCAAs; not a formulation trial. Populations from studies included in the review; no single population can be assigned.
Study duration
Protocols vary; no specific duration transfers to the product.
Limits / relevance to DK-7.4
An independent valine effect and relevance to the combination require specific evidence.
DOI · LIT
10.14814/phy2.15775
GLN · ingredient profile

L-Glutamine

LIT · ingredient / model
Nutritional / formulation function
Abundant amino acid involved in nitrogen metabolism and used as a substrate by multiple tissues.
Mechanism investigated
A cell study describes differential regulation of mTORC1 by glutamine and leucine, involving GATOR; this is an experimental mechanism, not a clinical response.
Evidence type / population
Mechanistic study in a cellular system (Jewell et al., Science, 2015); does not demonstrate product-level nutritional efficacy. Experimental cellular model; not a human population.
Study duration
Not applicable as a human-use duration; specific experimental protocol.
Limits / relevance to DK-7.4
Do not infer intestinal, immune, or muscle benefit from its presence in the blend.
DOI · LIT
10.1126/science.1259472
HMB · ingredient profile

β-Hydroxy β-Methylbutyrate (HMB)

LIT · ingredient / model
Nutritional / formulation function
Nutritional metabolite derived from leucine; its inclusion is part of the declared composition.
Mechanism investigated
Studied in relation to muscle metabolism and mass/strength outcomes; proposed mechanisms do not prove a response to the combination.
Evidence type / population
Meta-analysis of oral supplementation in people over 50, with heterogeneous studies and protocols (Li et al., 2025). People over 50 in the meta-analysis; not necessarily comparable to other groups.
Study duration
Varies across included studies; no single duration is established for this formulation.
Limits / relevance to DK-7.4
Pooled estimates do not predict individual or product outcomes; dose, duration, and eligibility should be checked in the article.
DOI · LIT
10.3389/fnut.2025.1522287
PS · ingredient profile

Phosphatidylserine

LIT · ingredient / model
Nutritional / formulation function
Phospholipid found in cell membranes; its role in the composition is not a demonstrated physiological effect.
Mechanism investigated
Investigated in exercise and stress-response studies; cortisol is a studied endpoint, not an assumed product outcome.
Evidence type / population
Systematic review of randomized trials on PS and athletic performance; outcomes and methods are heterogeneous (Welch et al., 2023). Participants in sports studies included in the review; populations and training vary.
Study duration
Variable protocols; no single duration can be assigned to the composition.
Limits / relevance to DK-7.4
Do not present a percentage reduction in cortisol or hormonal effect as a property of DK-7.4.
DOI · LIT
10.33545/27077012.2023.v4.i2c.209
PC · ingredient profile

Phosphatidylcholine

HYP · formulation
Nutritional / formulation function
Phospholipid component of the proposed matrix; its technological function depends on the composition and process actually used.
Mechanism investigated
Phospholipid organization guides technical questions about composition, stability and exposure; formulation details are discussed during diligence.
Evidence type / population
Formulation-specific technical discussion through institutional contact. No documented human DK-7.4 population.
Study duration
No documented product-use duration.
Limits / relevance to DK-7.4
Verify the final specification and label before attributing outcomes to the matrix. Do not infer liposomal delivery from the ingredient alone.
CRE · ingredient profile

Creatine Monohydrate

LIT · ingredient / model
Nutritional / formulation function
Participates in the creatine–phosphocreatine system, associated with buffering and rapid ATP resynthesis.
Mechanism investigated
Supports phosphocreatine-system availability in studied protocols; does not prove a combination benefit or matrix-mediated transport.
Evidence type / population
Consensus position stand on creatine safety and efficacy in exercise, sport, and medicine (Kreider et al., 2017). Literature includes different populations and contexts; outcomes depend on protocol and use case.
Study duration
Use protocols vary; no regimen or duration is assigned to the product.
Limits / relevance to DK-7.4
Consider total intake, renal status/individual conditions, and concomitant use with a professional; ingredient evidence does not replace label review.
DOI · LIT
10.1186/s12970-017-0173-z
D3K2 · ingredient profile

Vitamin D3 + K2 (MK-7)

LIT · ingredient / model
Nutritional / formulation function
D3 participates in calcium and phosphorus homeostasis; vitamin K is a cofactor for vitamin-K-dependent proteins. These functions are not product claims.
Mechanism investigated
Pathways involve the vitamin D receptor and carboxylation of vitamin-K-dependent proteins; clinical synergy is not inferred for this combination.
Evidence type / population
No trial reference for the DK-7.4 combination is presented here. No DK-7.4 population is documented; suitability depends on individual context.
Study duration
Not established for the product in this documentation.
Limits / relevance to DK-7.4
Confirm the specification and applicable regulatory limits/claims; concomitant use, especially vitamin K with vitamin K antagonists, requires professional assessment.
— 03Scientific Reference · Active Ingredients

What can already be documented

Data extracted from literature published between 2022 and 2025 — including systematic reviews, meta-analyses, and mechanistic studies of isolated ingredients.

LIT
Leucine · ingredient literature¹
+0.28kg
Isolated HMB · meta-analysis >50 y²
LPS
Phospholipid matrix · formulation architecture
DK
Product details · institutional inquiry
Ingredient
Mechanistic context
Evidence descriptor
Reference
L-Leucine
Mechanistic contextNutrient signaling associated with mTORC1 in ingredient literature; response varies with age, exercise, meal, and amino-acid availability.
Evidence descriptorMechanism · LIT
ReferenceEly et al., Clin Nutr 2023
HMB
Mechanistic contextOral-HMB meta-analysis: pooled lean-mass estimate +0.28 kg in people over 50; isolated-ingredient estimate, not this formula.
Evidence descriptor+0.28 kg lean mass
ReferenceLi et al., Front Nutr 2025
Phosphatidylserine
Mechanistic contextCortisol was an endpoint in sports literature; a systematic review judged evidence insufficient for firm endorsement.
Evidence descriptorEvidence insufficient
ReferenceWelch et al., J Sports Sci Nutr 2023
L-Isoleucine
Mechanistic contextA review evaluates dietary leucine and post-exercise protein synthesis; it does not demonstrate GLUT4 translocation or synergy in the DK-7.4 blend.
Evidence descriptorIngredient · LIT
ReferenceWilkinson, Physiol Rep 2023
Creatine
Mechanistic contextCreatine–phosphocreatine system and rapid ATP resynthesis; ingredient consensus does not validate matrix delivery or the complete product.
Evidence descriptorIngredient · LIT
ReferenceKreider et al., JISSN 2017

Magnitudes and mechanisms refer only to the cited ingredient sources; they are not evidence for DK-7.4. Final amounts require reconciliation against the master formula and label. This product does not replace professional advice.

— 04Assessment Design · Context
01

Delivery variability

Map matrix, timing, digestion, and metabolic context before comparing any response. The first question is not “which dose works?” but “what exposure was actually observed?”

02

Metabolic context

Energy deficit, age, exertion, and recovery should be treated as design variables — not noise. Different populations require explicitly defined comparators and endpoints.

03

Signaling and response

Separate ingredient mechanism, formulation characterization, and human outcome. Each layer answers a different question and needs a different measure.

04

Longitudinal evidence

Define safety, adherence, pharmacovigilance, and endpoints before attributing any outcome to the formulation. The next milestone is a testable question — not a promise.

Scientific Literature

Scientific References

Bibliographic DOI records have been checked. Each study's design, population and endpoint constrain the interpretation; a valid DOI does not verify the site's numerical claims or establish a result for DK-7.4.

1

Ely IA, Phillips BE, Smith K, Wilkinson DJ, Piasecki M, Breen L, Larsen MS, Atherton PJ.

A focus on leucine in the nutritional regulation of human skeletal muscle metabolism in ageing, exercise and unloading states.

Clinical Nutrition·2023·42(10):1849–1865
DOI10.1016/j.clnu.2023.08.010
LeucinemTORC1MPSBCAA
2

Li N, Wu X, Zhuang W, et al.

Effects of oral supplementation of β-hydroxy-β-methylbutyrate on muscle mass and strength in individuals over the age of 50: a meta-analysis.

Frontiers in Nutrition·2025·12:1522287
DOI10.3389/fnut.2025.1522287
HMBLean MassMeta-analysisn=1.935>50 years
3

Welch J, Bashir H, Daniels S.

The effect of phosphatidylserine supplementation on athletic performance: A systematic review of randomized clinical trials.

Journal of Sports Science and Nutrition·2023·4(2):170–175
DOI10.33545/27077012.2023.v4.i2c.209
PhosphatidylserineAthletic Performance7 estudosEvidência insuficiente
4

D'Hulst G, De Bock K.

Resistance exercise enhances long-term mTORC1 sensitivity to leucine.

Molecular Metabolism·2022·66:101615
DOI10.1016/j.molmet.2022.101615
mTORResistance ExerciseLeucineS6K1
5

Wilkinson K, Koscien CP, Monteyne AJ, Wall BT, Stephens FB.

Association of postprandial postexercise muscle protein synthesis rates with dietary leucine: A systematic review.

Physiological Reports·2023·11(15):e15775
DOI10.14814/phy2.15775
BCAALeucineMPSIsoleucineValine
6

Jewell JL, Kim YC, Russell RC, Yu FX, Park HW, Plouffe SW, Tagliabracci VS, Guan KL.

Differential regulation of mTORC1 by leucine and glutamine.

Science·2015·347(6218):194–198
DOI10.1126/science.1259472
GlutaminemTORC1GATOR2GATOR1
7

Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, Candow DG, Kleiner SM, Almada AL, Lopez HL.

International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine.

Journal of the International Society of Sports Nutrition·2017·14:18
DOI10.1186/s12970-017-0173-z
CreatineISSNPosicionamento científicoSafety em contexto
8

Wolfe RR, Goodenough RD, Wolfe MH, Royle GT, Nadel ER.

Isotopic analysis of leucine and urea metabolism in exercising humans.

Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology·1982·52(2):458–466
DOI10.1152/jappl.1982.52.2.458
LeucineMetabolism durante exercícioAnálise isotópica

References concern published ingredient literature, not studies of the complete formulation. Classification, authorized constituents, claims and notification of any finished supplement require review against current Brazilian rules and product documents.